MedTrace Logo

Ologen (OculusGen)-Glaucoma MMC Control Trial in India

NCT00449098 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-10-07

No results posted yet for this study

Summary

The purpose of this study is to compare the safety and effectiveness of the ologen (OculusGen) Biodegradable Collagen Matrix Implant and the MMC group in filtration surgery.

Conditions

Interventions

DEVICE

OculusGen Biodegradable Collagen Matrix Implant

Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant

DRUG

Trabeculectomy with MMC

Trabeculectomy with MMC

Sponsors & Collaborators

  • Pro Top & Mediking Company Limited

    lead INDUSTRY

Principal Investigators

  • Rajul S Parikh, MD · V. S. T. Glaucoma Services, L. V. Prasad Eye Institute,

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • India

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00449098 on ClinicalTrials.gov